Events & News

Events & News

Latest Innovations

Decoding Prostate Cancer: The Molecular Blueprint and Targeted Treatment Landscape (Part I)

09 September 2025

Latest Innovations

Prostate cancer (PC) is an androgen-driven, male-specific malignancy. According to The Lancet [1], it ranks as the second most common cancer in men globally, accounting for 15% of all male cancers. In the United States, PC is the most prevalent cancer among men.

Prostate cancer typically progresses slowly with an extended disease course, predominantly affecting men over 60 (who represent 60% of new cases). In its early stages, PC exhibits slow growth with favourable treatment outcomes—boasting a 5-year survival rate exceeding 99% with minimal mortality. However, in advanced stages, the cancer transforms from a localized lesion to a systemic disease, significantly complicating treatment, shortening patient survival, and dramatically increasing mortality rates. Clinical data shows that patients with metastatic prostate cancer have a 5-year survival rate of merely 30%.

Together with AmBeed Life Science , let's delve into the molecular underpinnings of prostate cancer—from the mechanisms driving its onset and progression to current targeted therapeutic strategies. Central to this exploration is the androgen receptor (AR) signalling pathway, a critical axis in prostate tumour biology. Join us as we unpack the latest research insights into AR-driven pathogenesis and precision treatment approaches.

In our next issue, we will shift focus to the challenges of drug resistance and therapeutic strategies targeting bone metastasis in advanced prostate cancer.

Pathogenesis and Targeted Therapeutic Strategies

The prostate gland comprises three distinct terminally differentiated epithelial cell types (Figure 1A): luminal cells, basal cells, and neuroendocrine cells. Luminal cells highly express CK8, CK18, and AR; basal cells predominantly express CK5 and p63; neuroendocrine cells are characterized by high Synaptophysin expression. In spontaneous prostate cancer mouse models, APRR2PB-Cre is commonly employed for conditional knockout of tumour suppressor genes, such as Pten and Trp53, in basal and luminal cells, inducing primary prostate cancer from these cell populations (Figure 1B). Research demonstrates that under androgen deprivation stress, epigenetic dysregulation, transcription factor networks, and metabolic adaptations collectively drive adenocarcinoma cells to transform toward a neuroendocrine cancer phenotype. However, whether neuroendocrine cells can directly transform into cancer remains unknown.

Prostate cancer development progresses through distinct phases (Figure 1C). It begins with abnormal proliferation of luminal cells forming prostatic intraepithelial neoplasia (PIN)—the early stage of prostate cancer. This is followed by localized prostate adenocarcinoma, where cancer cells proliferate but remain confined within the basement membrane. In the advanced stage, cancer cells breach the basement membrane, becoming locally metastatic. When cancer cells travel through the circulatory system to different sites, they form systemically metastatic advanced cancer. Since prostate cancer cells heavily depend on the androgen receptor (AR) signalling pathway, androgen deprivation therapy (ADT) serves as the first-line treatment for advanced cases. ADT works through either pharmacological blockade of the AR pathway or surgical intervention. However, some patients develop resistance after ADT treatment, progressing to castration-resistant prostate cancer (CRPC) with reduced androgen dependence. CRPC poses a significant threat to patients' lives, making its resistance mechanisms and potential solutions a major focus of current research.

Current targeted therapeutic approaches for prostate cancer include several key strategies (Figure 1D):

1. Targeting the AR signalling pathway: Prostate cancer cells depend heavily on AR and androgens for proliferation and survival. Androgen deprivation causes death in most cancer cells, with ADT producing positive responses in most patients.
2. Targeting the bone microenvironment: Bone metastasis affects 90% of patients with advanced prostate cancer. Treatments targeting these metastases can significantly improve survival rates.
3. Targeting PSMA: Prostate-Specific Membrane Antigen is a transmembrane glycoprotein with high expression in prostate cancer but low expression in normal tissues. PSMA-targeted antibody-drug conjugates (ADC) or radionuclides can selectively eliminate cancer cells.
4. Targeting DNA damage repair mechanisms: For patients with BRCA mutations, PARP inhibitor therapy can reduce mortality risk by 40%. The synthetic lethality between BRCA and PARP is a common treatment approach.
5. Targeting cell cycle pathways: Uncontrolled proliferation and cell cycle disruption are characteristic of prostate cancer. Inhibiting key regulatory kinases like CDK4/6 (using Palbociclib) effectively suppresses tumor cell growth.
6. Targeting PI3K/AKT/mTOR pathways: Prostate cancer often shows PTEN deficiency (a negative regulator that inhibits Akt activity), leading to hyperactive PI3K/AKT signalling. Inhibitors of this pathway effectively suppress cancer development.
7. Targeting epigenetic modifications: Drug resistance, reduced androgen dependence, and dysregulated gene expression often stem from abnormal epigenetic changes. Targeting specific modification sites—EZH2 (via GSK126), BET (via Birabresib), and HDAC (via Vorinostat)—can reduce resistance and restore androgen dependence.
8. Targeting additional proliferative pathways: Malignant prostate cancer cell growth also involves other signalling networks, including Wnt, TGF-β, VEGF, and MEK.

Figure 1. Prostate cancer progression and targeted therapies. [2][3]

The Androgen Receptor Signalling Pathway in Prostate Cancer

AR Signalling Pathway: Androgen synthesis occurs through the hypothalamic-pituitary-testicular axis (Figure 2B), producing testosterone (T). In the prostate, the enzyme SRD5A converts T to dihydrotestosterone (DHT), a more potent androgen. Abiraterone blocks androgen production by inhibiting CYP17A1, a key enzyme in androgen synthesis. Glucocorticoids (such as dexamethasone and hydrocortisone) suppress androgen production by inhibiting pituitary adrenocorticotropic hormone (ACTH), which disrupts the hypothalamic-pituitary-testicular axis. Similarly, gonadotropin-releasing hormone (GnRH) inhibitors or agonists achieve therapeutic effects by reducing serum androgen levels [4].

In its resting state, AR functions as a transcription factor bound to heat shock proteins (HSP) in the cytoplasm (Figure 2A). When stimulated by androgens, AR separates from HSP, binds to T or DHT, forms dimers, and travels into the nucleus via microtubules. There it binds to androgen response elements (ARE) to trigger gene expression. While HSP binding stabilizes AR, activation of the receptor tyrosine kinase (RTK) signalling pathway can phosphorylate AR, further enhancing its stability. AR directly controls target genes involved in proliferation, metabolism, differentiation evasion, and other processes. The downstream TMPRSS2-ERG fusion gene (found in 50% of prostate cancers) is one example that can inhibit tumor cell senescence and abnormally activate pro-proliferative signalling pathways. Enzalutamide works as an AR antagonist by binding to AR's ligand-binding domain (LBD), preventing AR-androgen binding and inhibiting the AR signalling pathway.

PARP or BRCA1/2 repair frequent DNA breaks in tumour cells (Figure 2C). In patients with BRCA1/2 mutations, using PARP inhibitors to block DNA damage repair can trigger prostate cancer cell apoptosis [5].

Figure 2. AR signalling pathway. [4][6]

Supporting Your Research with The Right Tools

Decoding the molecular intricacies of prostate cancer, from androgen signalling to treatment resistance, requires not only insight, but also the right research tools. At AmBeed Life Science, we are proud to support scientists with a growing portfolio of high-purity small molecules specifically relevant to prostate cancer research.

Featured Catalog of Research-Grade Inhibitors for Prostate Cancer Studies:

· Androgen Receptor (AR) Pathway: Enzalutamide analogs for disrupting androgen-mediated transcriptional programs.
· DNA Damage Repair: PARP inhibitors (e.g., Olaparib analogs) for synthetic lethality in BRCA-deficient tumour models.
· PI3K/AKT/mTOR Pathways: Small-molecule inhibitors for dissecting downstream signalling in PTEN-deficient prostate cancer.
· Cell Cycle Regulation: CDK4/6 inhibitors (e.g., Palbociclib) to induce G1-phase arrest and suppress tumour proliferation.
· Epigenetic Modulators: EZH2 inhibitors (GSK126), BET inhibitors (Birabresib), and HDAC inhibitors (Vorinostat) to reverse transcriptional silencing and combat resistance.
· Tumour Microenvironment & Bone Metastasis: Compounds targeting VEGF, TGF-β, and PSMA for modulating the metastatic niche and enhancing selectivity.

Whether you are investigating early tumour-genesis, castration-resistant progression, or metastatic behaviour, AmBeed is here to provide reliable reagents that empower discovery.

Together, let’s drive innovation from the bench to the real world.

Follow us on LinkedIn and stay at the forefront of Science.

References

[1]James, Nicholas D et al. The Lancet, Volume 403, Issue 10437, 1683 - 1722.

[2]Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018). Genetics and biology of prostate cancer. Genes & development, 32(17-18), 1105–1140.

[3]He, Y., et al. (2022). Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal transduction and targeted therapy, 7(1), 198.

[4]Desai, K., McManus, J. M., & Sharifi, N. (2021). Hormonal Therapy for Prostate Cancer. Endocrine reviews, 42(3), 354–373.

[5]Bieńkowski, M., Tomasik, B., Braun, M., & Jassem, J. (2022). PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. Cancer treatment reviews, 104, 102359.

[6]Swami, U., McFarland, T. R., Nussenzveig, R., & Agarwal, N. (2020). Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends in cancer, 6(8), 702–715.

Prev: Pure-blue single-layer organic light-emitting diodes based on trap-free hyperfluorescence

Next: Site-selective Ru-catalysed saturation of unactivated arenes via directed 6π activation